What is the next earnings date for CUE stock?
CUE BIOPHARMA INC (CUE) will report earnings on 2026-05-12.
CUE BIOPHARMA INC (CUE) Forecast, Price Target & Analyst Ratings
NASDAQ:CUE • US22978P1066
Current stock price
12.455 USD
-5.47 (-30.54%)
At close:
13.9135 USD
+1.46 (+11.71%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CUE BIOPHARMA INC (CUE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.11
- Revenue Estimate
- 2.525M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $12.46 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
-20.00%
Price Target Summary
The average price target has been revised downward by 20% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
CUE was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CUE.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed CUE. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-25 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-04-02 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2024-08-20 | Stifel | Maintains | Buy -> Buy |
| 2024-07-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-04-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-09 | Stifel | Maintains | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-13 | Jefferies | Initiate | Buy |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-06-15 | Stifel | Reiterate | Buy -> Buy |
| 2023-05-15 | JMP Securities | Reiterate | Outperform -> Outperform |
| 2023-03-22 | Oppenheimer | Reiterate | Outperform |
| 2023-03-22 | Stifel | Maintains | Buy |
| 2022-11-21 | Piper Sandler | Initiate | Overweight |
| 2022-08-24 | Oppenheimer | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.11
- Revenue Estimate
- 2.525M
- Revenue Q2Q
- 499.76%
- EPS Q2Q
- 34.65%
- Number of Analysts
- 2
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CUE is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.11 USD and the consensus revenue estimate is 2.52M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.49M 339.20% | 9.287M 69.16% | 27.466M 195.75% | 1.01M -96.32% | 1.01M | 54.995M 5,345.05% | 1.01M -98.16% | 1.01M | 1.01M | 47.773M 4,630.00% | 98.879M 106.98% | |
| EBITDA YoY % growth | -51.436M 2.18% | -41.196M 19.91% | -25.563M 37.95% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -51.992M 2.82% | -41.593M 20.00% | -26.521M 36.24% | -48.985M -84.70% | -44.44M 9.28% | -11.666M 73.75% | -60.499M -418.61% | -65.448M -8.18% | -70.801M -8.18% | -74.74M -5.56% | -25.654M 65.68% | |
| Operating Margin | -947.03% | -447.86% | -96.56% | -4,850.00% | -4,400.00% | -21.21% | -5,990.00% | -6,480.00% | -7,010.00% | -156.45% | -25.94% | |
| EPS YoY % growth | -1.11 26.00% | -0.75 32.43% | N/A 44.79% | -0.59 -41.46% | -0.61 -3.45% | 0.24 140.00% | 1.50 520.83% | -0.46 -130.87% | -0.47 -2.17% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 34.65% | -0.12 -34.67% | -0.12 -73.14% | -0.13 -30.00% |
| Revenue Q2Q % growth | 2.525M 499.76% | 2.525M -14.52% | 2.525M 17.50% | 2.525M -88.49% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.11M 9.67% | -11.918M -38.02% | -12.625M -67.35% | -13.433M -786.06% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
37.25%
EPS Next 5 Year
-2.33%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
89.51%
Revenue Next 5 Year
-34.02%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CUE BIOPHARMA INC / CUE Forecast FAQ
Can you provide the consensus estimates for CUE BIOPHARMA INC next earnings?
The consensus EPS estimate for the next earnings of CUE BIOPHARMA INC (CUE) is -0.11 USD and the consensus revenue estimate is 2.52M USD.
How many analysts have analysed CUE BIOPHARMA INC (CUE)?
The number of analysts covering CUE BIOPHARMA INC (CUE) is 5.